Mattias Klintemar

Veloves mission is to beat vans. We create livable city centers and meet climate targets by our unique system of e-cargo bikes, tech, hubs and riders. We handle last-mile deliveries within the city for e-customers and urban logistics. Currently live in Stockholm, Gothenburg, Malmö and Copenhagen.

Palette Life Sciences is a fully integrated medical device company providing a wide range of products and services that improve quality of life of patients. Our portfolio of products focuses on treating conditions in urology/urogynecology disorders, colorectal conditions, radiotherapy, and interventional oncology procedures. For physicians, researchers, and inventors alike, progress begins with a natural curiosity and the drive to do more. By discovering and applying new applications of proven medicine to uncommon, or difficult to treat conditions, we can address the needs of patients often overlooked by traditional medical companies. Inspired by innovation and empathy, we see endless possibilities in expanding on proven technologies to elevate patient care. The foundation for all of our breakthrough products is Non-Animal Stabilized Hyaluronic Acid (NASHA®). NASHA has been proven safe and effective for more than two decades in over 50 million medical procedures worldwide. Barrigel® - the first and only FDA-cleared hyaluronic acid rectal spacer, minimizing the side effects of radiation therapy for prostate cancer patients. Barrigel is available in the US, Australia and Europe. Deflux® - the only FDA-approved injectable treatment for vesicoureteral reflux (VUR), a urinary defect that affects 1% of children worldwide. Deflux for VUR is available in the US, Canada, Europe, Japan, Latin America, Australia and New Zealand. Also indicated for stress urinary incontinence (SUI) in women, Deflux for SUI is available in Canada and Europe. Solesta® - the only FDA-approved injectable treatment for fecal incontinence, a debilitating health problem afflicting about 2% of people worldwide. Solesta is available in the US and Europe. Palette Life Sciences is headquartered in Stockholm, Sweden, with offices in Santa Barbara, California, Dallas, Texas, Sydney, Australia and Tokyo, Japan. Learn more at palettelifesciences.com.

DBT grundades 2017 med ambitionen att ge små och medelstora bolag bättre finansieringsalternativ. DBT erbjuder långsiktiga företagslån från 5 miljoner kronor till svenska aktiebolag inom alla branscher. En bred intern expertis, kombinerat med en avancerad plattform för analys av realtidsdata, möjliggör snabbare handläggning och bättre analys. DBT är en del av NOBA Bank Group och stöttas av Europeiska Investeringsfonden (EIF).

Moberg Pharma AB (publ) är ett svenskt läkemedelsbolag med fokus på kommersialisering av egenutvecklade läkemedel baserade på beprövade substanser. Bolagets tillgång MOB-015 är en ny utvärtes behandling av nagelsvamp. Kliniska fas 3-studier av fler än 800 patienter för MOB-015 indikerar att produkten har potential att bli den framtida marknadsledaren inom nagelsvamp. Moberg Pharma har avtal med kommersiella partners på plats i bland annat Europa och Kanada och bolagets målsättning är att få första marknadsgodkännande och påbörja lansering av MOB-015 under 2023. Moberg Pharma har huvudkontor i Stockholm och bolagets aktie är noterad under Small Cap på Nasdaq Stockholm (OMX: MOB).

Phoniro is part of ASSA ABLOY Global Solutions and has innovative products, solutions, and support designed specifically for Senior Living Communities and Home Health Care agencies. We have been at the forefront of driving key innovation and technology within the industry by providing products that increase satisfaction and convenience for your staff and residents. We build and design advanced locking solutions, access control, and analytical data custom to your organization. Additionally, our innovative technology evolve with the organization’s needs, increasing efficiencies, enhancing security, and providing seamless maintenance.

Oatly is a company built on the idea of change. We exist to make it easy for people to eat better and live healthier lives without recklessly taxing the planet’s resources in the process. This is why we come to work every day. Headquartered in Malmö, Sweden, the Oatly brand is available in more than 20 countries across Europe, North America and Asia. Visit oatly.com to learn more.

Veloves mission is to beat vans. We create livable city centers and meet climate targets by our unique system of e-cargo bikes, tech, hubs and riders. We handle last-mile deliveries within the city for e-customers and urban logistics. Currently live in Stockholm, Gothenburg, Malmö and Copenhagen.

Biosergen’s antifungal drug candidate, BSG005, is the fruit of a groundbreaking effort over the last two decades by SINTEF (one of Europe’s largest independent research organizations) and the Norwegian University of Science and Technology (NTNU) to develop an improved version of Nystatin, a naturally occurring fungicidal chemical in the bacterial strain Streptomyces noursei. Work that to date has been published in more than 20 international peer reviewed scientific publications. BSG005 has been shown to have a broad spectrum of action. At similar dose levels, the drug demonstrates a three to four times in vivo potency advantage over the current standard of care for patients not responding to Azole and Echinocandin treatment. With this product profile BSG005 will fill the need for a product that offers fungicidal efficacy against a broad range of fungal strains. BSG005 appears to be without the gaps due to resistance development seen in other antifungals. Most importantly, in the GLP-tox tests and in recognized animal models it lacks the severe kidney toxicity seen with Amphotericin B formulations. BSG005 has also shown effect against resistant fungal strains and strains that have been difficult to treat with the drugs available on the market.

Palette Life Sciences is a fully integrated medical device company providing a wide range of products and services that improve quality of life of patients. Our portfolio of products focuses on treating conditions in urology/urogynecology disorders, colorectal conditions, radiotherapy, and interventional oncology procedures. For physicians, researchers, and inventors alike, progress begins with a natural curiosity and the drive to do more. By discovering and applying new applications of proven medicine to uncommon, or difficult to treat conditions, we can address the needs of patients often overlooked by traditional medical companies. Inspired by innovation and empathy, we see endless possibilities in expanding on proven technologies to elevate patient care. The foundation for all of our breakthrough products is Non-Animal Stabilized Hyaluronic Acid (NASHA®). NASHA has been proven safe and effective for more than two decades in over 50 million medical procedures worldwide. Barrigel® - the first and only FDA-cleared hyaluronic acid rectal spacer, minimizing the side effects of radiation therapy for prostate cancer patients. Barrigel is available in the US, Australia and Europe. Deflux® - the only FDA-approved injectable treatment for vesicoureteral reflux (VUR), a urinary defect that affects 1% of children worldwide. Deflux for VUR is available in the US, Canada, Europe, Japan, Latin America, Australia and New Zealand. Also indicated for stress urinary incontinence (SUI) in women, Deflux for SUI is available in Canada and Europe. Solesta® - the only FDA-approved injectable treatment for fecal incontinence, a debilitating health problem afflicting about 2% of people worldwide. Solesta is available in the US and Europe. Palette Life Sciences is headquartered in Stockholm, Sweden, with offices in Santa Barbara, California, Dallas, Texas, Sydney, Australia and Tokyo, Japan. Learn more at palettelifesciences.com.

DBT grundades 2017 med ambitionen att ge små och medelstora bolag bättre finansieringsalternativ. DBT erbjuder långsiktiga företagslån från 5 miljoner kronor till svenska aktiebolag inom alla branscher. En bred intern expertis, kombinerat med en avancerad plattform för analys av realtidsdata, möjliggör snabbare handläggning och bättre analys. DBT är en del av NOBA Bank Group och stöttas av Europeiska Investeringsfonden (EIF).